Andrew L. Himelstein

967 total citations
17 papers, 595 citations indexed

About

Andrew L. Himelstein is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Surgery. According to data from OpenAlex, Andrew L. Himelstein has authored 17 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Andrew L. Himelstein's work include Radiopharmaceutical Chemistry and Applications (6 papers), RNA Interference and Gene Delivery (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Andrew L. Himelstein is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (6 papers), RNA Interference and Gene Delivery (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Andrew L. Himelstein collaborates with scholars based in United States and Italy. Andrew L. Himelstein's co-authors include Stephen S. Grubbs, Paul J. Novotny, Charles L. Shapiro, Léonard V. Smith, Ira Pastan, Christine Richardson, S Podda, Jared C. Foster, A Bank and Maureen Ward and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Andrew L. Himelstein

16 papers receiving 587 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew L. Himelstein United States 9 339 226 127 109 96 17 595
Chad A. Hamilton United States 11 290 0.9× 214 0.9× 52 0.4× 117 1.1× 62 0.6× 26 1.0k
Valentine Gauthier United States 13 77 0.2× 165 0.7× 35 0.3× 43 0.4× 105 1.1× 21 562
Grant R. Goodman United States 12 236 0.7× 130 0.6× 18 0.1× 56 0.5× 38 0.4× 16 552
R. Fischer Germany 15 136 0.4× 166 0.7× 26 0.2× 33 0.3× 42 0.4× 41 741
Mitsutoshi Kurosawa Japan 13 209 0.6× 119 0.5× 26 0.2× 108 1.0× 16 0.2× 49 610
Jelle W. Kylstra United States 8 310 0.9× 91 0.4× 22 0.2× 62 0.6× 97 1.0× 14 619
Silvana Capalbo Italy 15 166 0.5× 144 0.6× 43 0.3× 18 0.2× 20 0.2× 37 669
Lode Goethals Belgium 12 210 0.6× 258 1.1× 68 0.5× 83 0.8× 134 1.4× 31 688
Masaaki Nishitani Japan 15 220 0.6× 227 1.0× 21 0.2× 170 1.6× 13 0.1× 35 568
Shane White Australia 17 465 1.4× 233 1.0× 45 0.4× 42 0.4× 70 0.7× 46 835

Countries citing papers authored by Andrew L. Himelstein

Since Specialization
Citations

This map shows the geographic impact of Andrew L. Himelstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew L. Himelstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew L. Himelstein more than expected).

Fields of papers citing papers by Andrew L. Himelstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew L. Himelstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew L. Himelstein. The network helps show where Andrew L. Himelstein may publish in the future.

Co-authorship network of co-authors of Andrew L. Himelstein

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew L. Himelstein. A scholar is included among the top collaborators of Andrew L. Himelstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew L. Himelstein. Andrew L. Himelstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Shapiro, Charles L., James P. Moriarty, Stacie B. Dusetzina, et al.. (2017). Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of Clinical Oncology. 35(35). 3949–3955. 49 indexed citations
2.
Himelstein, Andrew L., Jared C. Foster, James Khatcheressian, et al.. (2017). Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. JAMA. 317(1). 48–48. 216 indexed citations
3.
Himelstein, Andrew L., Rui Qin, Paul J. Novotny, et al.. (2015). CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.. Journal of Clinical Oncology. 33(15_suppl). 9501–9501. 14 indexed citations
4.
Tomblyn, Michael, Thomas E. Witzig, Andrew L. Himelstein, et al.. (2013). Anti-CD22 radioimmunotherapy (RIT) combined with anti-CD20 immunotherapy in aggressive non-Hodgkin lymphoma (NHL): Phase I results. 54. 1368–1368. 1 indexed citations
5.
Tomblyn, Michael, Thomas E. Witzig, Andrew L. Himelstein, et al.. (2012). Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results. Blood. 120(21). 3680–3680. 1 indexed citations
6.
Tomblyn, Michael, Rebecca Elstrom, Andrew L. Himelstein, et al.. (2012). Novel combination of anti-CD22 radioimmunotherapy and anti-CD20 immunotherapy targeting two different antigens in non-Hodgkin lymphoma (NHL): Initial clinical experience. 53. 500–500. 2 indexed citations
7.
Rosenberg, Jonathan E., Susan Halabi, Ben L. Sanford, et al.. (2008). Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Annals of Oncology. 19(5). 946–950. 39 indexed citations
8.
Rosenberg, Jonathan E., Susan Halabi, Ben L. Sanford, et al.. (2006). CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC). Journal of Clinical Oncology. 24(18_suppl). 4582–4582. 3 indexed citations
9.
Guarino, Michael J., Gregory A. Masters, David D. Biggs, et al.. (2005). Barriers exist to patient participation in clinical trials. Journal of Clinical Oncology. 23(16_suppl). 6015–6015. 6 indexed citations
10.
Martin, Eric S., Rossano Cesari, Francesca Pentimalli, et al.. (2003). The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proceedings of the National Academy of Sciences. 100(20). 11517–11522. 45 indexed citations
11.
12.
Himelstein, Andrew L., et al.. (1993). Long‐term high‐level expression of human β‐globin occurs following transplantation of transgenic marrow into irradiated mice. American Journal of Hematology. 42(3). 254–261.
13.
Podda, S, Maureen Ward, Andrew L. Himelstein, et al.. (1992). Transfer and expression of the human multiple drug resistance gene into live mice.. Proceedings of the National Academy of Sciences. 89(20). 9676–9680. 172 indexed citations
14.
Richardson, Christine, Maureen Ward, Andrew L. Himelstein, et al.. (1992). Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood. 80(12). 3106–3111. 19 indexed citations
15.
Ward, Maureen, Andrew L. Himelstein, Léonard V. Smith, et al.. (1992). Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood. 80(12). 3106–3111. 2 indexed citations
16.
Johnson, William, et al.. (1986). Arterial intimal embrittlement A possible factor in atherogenesis. Atherosclerosis. 59(2). 161–171. 10 indexed citations
17.
Garlick, Robert, et al.. (1984). Acetylation of human fetal hemoglobin occurs throughout erythroid cell maturation. Biochimica et Biophysica Acta (BBA) - General Subjects. 799(1). 29–37. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chad A. Hamilton Breakdown of academic impact, for papers by Valentine Gauthier Breakdown of academic impact, for papers by Grant R. Goodman Breakdown of academic impact, for papers by R. Fischer Breakdown of academic impact, for papers by Mitsutoshi Kurosawa Breakdown of academic impact, for papers by Jelle W. Kylstra Breakdown of academic impact, for papers by Silvana Capalbo Breakdown of academic impact, for papers by Lode Goethals Breakdown of academic impact, for papers by Masaaki Nishitani Breakdown of academic impact, for papers by Shane White
Rankless by CCL
2026